TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22577172
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg rhTSH (n = 42)
Study: 20979754
Drug: Esmolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1 mg/kg intravenously followed by 150 microg x kg(‐1) x min(‐1) intravenous infusion)
Study: 15465443
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of l-dopa
Study: 11833926
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi intervention (6-month, twice a week)
Study: 7979119
Drug: 5% EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% EMLA cream (lidocaine and prilocaine), applied to the venepuncture site for at least 60 minutes.
Study: 7979119
Drug: Placebo cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, applied to the venepuncture site for at least 60 minutes.
Study: 864062
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment controls
Study: 864062
Drug: alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: alternative treatment conditions
Study: 21569574
Drug: Neoadjuvant ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant ADT for ≥10 months after PSA reached < 0.2 ng/ml
Study: 21569574
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery
Study: 17140281
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone 40-80 mg twice daily for acute illness
Study: 17140281
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone 20-80 mg twice daily for chronic schizophrenia or schizoaffective disorder
Study: 17140281
Drug: Intramuscular ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ziprasidone for acute agitation
Study: 9402180
Drug: GEM 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM 1,200 mg/m2 + VNR 25 mg/m2
Study: 9402180
Drug: GEM 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM 1,200 mg/m2 + VNR 20 mg/m2
Study: 9402180
Drug: GEM 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM 1,000 mg/m2 + VNR 25 mg/m2
Study: 8218536
Drug: Initial induction
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial induction consolidation chemotherapy for newly diagnosed AML
Study: 2438841
Drug: Blue-green argon
Normalized name: BLUE GREEN ALGAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue-green argon laser treatment
Study: 2438841
Drug: Red krypton
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red krypton laser treatment
Study: 14511962
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Study: 14511962
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Study: 10389710
Drug: Negative fetal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative fetal fibronectin test with 0.5 mg PGE2 gel
Study: 8896855
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g EMLA cream
Study: 1670586
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) plus zidovudine (ZDV), daily doses of IL-2 from 1.5 to 12 x 10(6) IU/m2
Study: 1670586
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) plus zidovudine (ZDV), higher doses of IL-2
Study: 4072925
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 to 50 mg/day)
Study: 30306399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of undirected movement and cognitive load
Study: 20188847
Drug: Systemic theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic theophylline (nonselective adenosine receptor antagonist)
Study: 20188847
Drug: Inhaled lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lidocaine (local anesthetic)
Study: 15502060
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with 0.08% bupivacaine and fentanyl 1.6 microg/mL
Study: 8349066
Drug: Oral omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omeprazole, 40 mg per day (n = 31)
Study: 8349066
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy (adrenaline 1:10,000 plus polidocanol 1% injection associated with oral ranitidine 300 mg per day) (n = 21)
Study: 28419997
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted soluble plasma leptin receptor (sOB-R) levels
Study: 26332539
Drug: USL261 (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL261 (2.5, 5.0, and 7.5 mg)
Study: 26332539
Drug: MDZ-inj IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ-inj IN (5.0 mg)
Study: 26332539
Drug: MDZ-inj IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ-inj IV (2.5 mg)
Study: 24172626
Drug: Systemic peroral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic peroral antibiotics
Study: 21444869
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Study: 21444869
Drug: 4-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Study: 16865997
Drug: Oral‐B Sonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Sonic Complete
Study: 16865997
Drug: Oral‐B Indicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Indicator (manual)
Study: 12953289
Drug: Immunoglobulin (IgG)
Normalized name: immunoglobulin A
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (IgG) enzyme‐linked immunosorbent assay (ELISA) for measuring serum antibody concentrations
Study: 11062357
Drug: Alendronate (ALN;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (ALN; 10 mg/day) for 2 years
Study: 11062357
Drug: Alendronate (ALN;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (ALN; 10 mg/day) for 3 years
Study: 9425591
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with a mixture of multiple allergen extracts
Study: 9425591
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy using synthetic fragments of the major allergen responsible for allergic reactions to cats
Study: 8375429
Drug: Bromocriptine-levodopa combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine-levodopa combination therapy
Study: 3758170
Drug: Naloxone (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4, 1.2, 3.6, 10.8, 32.4, 97.2 mg)
Study: 30721950
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized P4 (3 × 200 mg/d IM)
Study: 30721950
Drug: E2 (5
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 (5 mg IM) and oral placebo
Study: 30721950
Drug: E2 IM
Normalized name: Estradiol Intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 IM and oral micronized P4
Study: 21177179
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy plus sulfasalazine delivered via a colon therapy system
Study: 21177179
Drug: Sulfasalazine delivered
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine delivered via colon therapy system
Study: 9725371
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of local anesthetics (bupivacaine) and opioid analgesics (fentanyl) through a thoracic epidural catheter
Study: 16509426
Drug: Pharmacotherapy by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy by fluvoxamine
Study: 16509426
Drug: Controlled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled therapy
Study: 10767520
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate plus L-thyroxine (75 mcg/day for 3 months)
Study: 10767520
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg/day for 5 days/month for 3 months)
Study: 10767520
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate plus L-thyroxine
Study: 6437815
Drug: TTS‐NTG (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS‐NTG (25 mg per 10 cm2)
Study: 31656173
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (ET) 3 times per week for 12 weeks
Study: 19067606
Drug: 3rd dose
Normalized name: CEPHALOSPORIN 3RD GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd dose of 1.25 microg H5N1 vaccine
Study: 19067606
Drug: 3rd dose
Normalized name: CEPHALOSPORIN 3RD GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd dose of 2.5 microg H5N1 vaccine
Study: 19067606
Drug: 3rd dose
Normalized name: CEPHALOSPORIN 3RD GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd dose of 5 microg H5N1 vaccine
Study: 19067606
Drug: 3rd dose
Normalized name: CEPHALOSPORIN 3RD GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd dose of 10 microg H5N1 vaccine
Study: 17544875
Drug: Single-dose inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose inactive trivalent influenza vaccine
Study: 17544875
Drug: Infliximab and
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab and immunomodulatory therapy
Study: 15718325
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention (six weekly sessions of 2 hours)
Study: 3524182
Drug: Streptokinase (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1.0 million units) followed by 72 hours of heparin infusion
Study: 3524182
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by heparin infusion
Study: 2493413
Drug: 1.5 mg/h
Normalized name: dextroamphetamine 1.5 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/h NTG infusion
Study: 2493413
Drug: 1.5 mg/h
Normalized name: dextroamphetamine 1.5 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/h NTG infusion after 12-hour infusion-free interval
Study: 25037243
Drug: Intravitreal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal diclofenac (IVD) - 500 μg/0.1 ml
Study: 25037243
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) - 1.25 mg
Study: 23980355
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy + Xuebijing (XBJ)
Study: 17987348
Drug: Physicians' responses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians' responses to patients' requests for antidepressants
Study: 15798812
Drug: Anti-retroviral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-retroviral therapy plus N-acetyl-L-cysteine (NAC) supplementation (600 mg/day)
Study: 15798812
Drug: Anti-retroviral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-retroviral therapy plus placebo
Study: 11789125
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (donepezil, rivastigmine, metrifonate)
Study: 30789575
Drug: Supplementary strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary strength training program (twice per week for 8 weeks)
Study: 22027191
Drug: Immunonutrition (IM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition (IM) group: 750 ml of IMPACT plus half‐size hospital meals orally from 5 days before to the day before surgery
Study: 31778599
Drug: Total incidence
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total incidence of allelic disorders of low drug absorption and metabolism
Study: 26867336
Drug: Intrathecal isobaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal isobaric bupivacaine 8.121 mg
Study: 26867336
Drug: Intrathecal isobaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal isobaric bupivacaine 9.012 mg
Study: 14522153
Drug: Post-treatment life
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment life expectancy and survival in females from more-deprived areas
Study: 31056681
Drug: Caffeine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (median 1.6 mg/L for dipyridamole; 7.4 mg/L for regadenoson)
Study: 28525981
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg orally 1 hour before anesthesia and Ramosetron 0.3 mg intravenously at the end of surgery (Group GR)
Study: 28525981
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg orally 1 hour before anesthesia (Group G)
Study: 28525981
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg intravenously at the end of surgery (Group R)
Study: 26375824
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy (morphine equivalents)
Study: 20464539
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E (VCE) administration before anesthesia with desflurane
Study: 20464539
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E (VCE) administration
Study: 11518436
Drug: Instrumental Enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Instrumental Enrichment (dynamic cognitive treatment)
Study: 11518436
Drug: Traditional occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional occupational therapy methods (control group)
Study: 9844792
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg/70 kg bolus and 3.5 mg/70 kg/hour for 4 hours)
Study: 9844792
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and M-6-G combination
Study: 9844792
Drug: M-6-G (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-6-G (doses producing plasma concentrations identical, 2x, or 3x higher than morphine)
Study: 8822914
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) at an initial dosage of 20 mg/kg/d for 6 months
Study: 2184135
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus poly(A).poly(U)
Study: 6788319
Drug: Diazepam (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (25 mg daily)
Study: 6788319
Drug: Promethazine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (125 mg daily)
Study: 30556414
Drug: Desoximetasone 0.25%
Normalized name: DESOXIMETASONE 0.25% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone 0.25% spray plus twice‐daily phone call reminders
Study: 27852718
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (HIIT) consisting of 10 high-intensity (85-90% peak power output) and 10 low-intensity (20-25% peak power output) intervals, each lasting 1 minute, for 8 weeks, twice weekly.
Study: 27852718
Drug: Moderate-intensity steady-state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity steady-state training (MISS) following usual care recommendations, adhering to UK guidelines (>20 minutes continuous exercise at 40-70% heart rate reserve), for 8 weeks, twice weekly.
Study: 20424418
Drug: 0.7 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/m2/day biosynthetic GH
Study: 20424418
Drug: 1.4 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 mg/m2/day biosynthetic GH
Study: 15730354
Drug: Various medications
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various medications (specific medications not detailed)
Study: 9043535
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 7 mg over 8 hours via metered-dose inhaler (MDI) attached to a holding chamber
Study: 9043535
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in the same fashion as BDP
Study: 2438966
Drug: Antihistamine/decongestant
Normalized name: ANTIHISTAMINE/DECONGESTANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine/decongestant
Study: 29787355
Drug: Lavender cream
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender cream and footbath
Study: 29787355
Drug: Lavender cream
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender cream alone
Study: 20335158
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) and azithromycin (10 mg/kg daily, intravenously)
Study: 20335158
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg daily, intravenously)
Study: 20335158
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (TCM and WM)
Study: 15780168
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate brachytherapy monotherapy
Study: 15780168
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy options
Study: 15780168
Drug: Matched analyses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched analyses with uniform patient treatment and pathological review
Study: 16245220
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg/kg/day)
Study: 1888818
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine nocte
Study: 1888818
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine nocte
Study: 30080254
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol self-administration after 2 weeks of abstinence
Study: 27997653
Drug: Pritelivir 100
Normalized name: Pritelivir
DrugBank: Pritelivir (DB11844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pritelivir 100 mg daily for 28 days
Study: 27997653
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg daily for 28 days
Study: 24488184
Drug: Direct-to-consumer advertising
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-to-consumer advertising (DTCA) about Cymbalta (an antidepressant)
Study: 22281110
Drug: PPI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI and rebamipide combination therapy
Study: 16390780
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement (2 mg estradiol/day, orally for 90 days)
Study: 11940322
Drug: Intravenous rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rt-PA therapy plus rescue intracoronary stenting
Study: 9804012
Drug: Dynamic CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic CT with intravenous administration of 40 ml Ioversol (5 cc/s)
Study: 8904479
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment for 'silent' PDA
Study: 203832
Drug: Clofibrate and
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibrate and m-Inositolnicotinate (1.5 g Clofibrate and 1.2 g m-Inositolnicotinate daily)
Study: 203832
Drug: Clofibrate or
Normalized name: clofibrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate or clofibrinic acid (monotherapy)
Study: 203832
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Clofibrate with m-Inositolnicotinate)